Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up

Authors
Publication date
20 May 2012
Publisher
'American Society of Clinical Oncology (ASCO)'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Deakin Research Online

    redirect
    oaioai:dro.deakin.edu.au:DU:30060...
    Last time updated on 27/02/2014